SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Elkin: Talking about the importance of pediatric eye health and safety
Rachitskaya: Archway found incidence of retinal fluid at Week 96 was generally comparable across treatment arms
Emanuel: Educating patients diagnosed with cataracts is key for physicians
